Floatz logo

Carboplatin

Lung Large Cell Carcinoma

National Cancer Institute (NCI)Small moleculePhase 4 / ApprovedActive
A
80/ 100
Provisional rating · Methodology v0.2

Rating breakdown

Clinical Evidence
70/ 100
Competitive Position
95/ 100

Competitive context

14 Active assets in the Lung Large Cell Carcinoma cohort.

Asset / SponsorPhaseRating
CIS-DIAMMINEDICHLOROPLATINUM II
National Cancer Institute (NCI)
Phase 3BBB
Etoposide
Barbara Ann Karmanos Cancer Institute
Phase 3BBB
Vinorelbine Ditartrate
AIO-Studien-gGmbH
Phase 3BB
Gefitinib
National Cancer Institute (NCI)
Phase 3BB
Docetaxel
Korean South West Oncology Group
Phase 3BB

View all 31 →

Same molecule, other indications

Carboplatin is also rated in:

non-small cell squamous lung carcinomaActive
BBB
Indicative · Phase 3
76 / 100
View asset →
primary peritoneal carcinomaActive
BBB
Indicative · Phase 3
76 / 100
View asset →
squamous cell lung carcinomaActive
BBB
Indicative · Phase 3
76 / 100
View asset →

Need depth?

Order a full diligence report on this asset.

Order report →

Are you the sponsor?

Submit your data room for a Verified Rating. The public-data rating remains visible alongside.

Contact →